Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 6-K (Third Quarter Report)
Reporting Period: Quarter and nine months ended September 30, 2007
Business Overview: Oncolytics is a development-stage biotechnology company focused on the development of REOLYSIN®, a potential cancer therapeutic based on reovirus. The company has not been profitable since its inception and expects to continue incurring substantial losses until commercial viability is achieved.
Key Financial Metrics
| Metric | Q3 2007 | Q3 2006 | 9 Months 2007 | 9 Months 2006 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,763,901) | $(3,425,169) | $(11,556,714) | $(9,407,419) |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.09) | $(0.29) | $(0.26) |
| Research & Development Expenses | $2,890,644 | $2,705,746 | $8,815,255 | $6,582,687 |
| Operating Expenses | $880,158 | $766,618 | $2,798,630 | $2,789,647 |
| Cash and Cash Equivalents (End of Period) | $3,326,374 | $3,957,086 | $3,326,374 | $3,957,086 |
| Total Cash & Short-Term Investments | $28,191,464 | $31,495,000 | $28,191,464 | $31,495,000 |
| Working Capital | $26,343,848 | $25,719,870 | $26,343,848 | $25,719,870 |
| Long-Term Debt | $0 | $150,000 | $0 | $150,000 |
Note: The $150,000 Alberta Heritage Foundation loan was reclassified to fair value and reduced to zero in the deficit upon adoption of new accounting standards in 2007.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the nine months ended September 30, 2007, increased by approximately $2.15 million compared to the same period in 2006, driven primarily by higher R&D expenses.
- R&D Expense Growth: R&D expenses rose to $8.82 million (9 months 2007) from $6.58 million (9 months 2006). This increase was due to:
- Clinical Trials: Direct clinical trial expenses increased to $2.80 million from $1.78 million as the company expanded from four to seven actively enrolling trials.
- Manufacturing: Manufacturing and process development expenses increased to $3.55 million from $2.75 million due to increased production runs and vial filling activities.
- Salaries: R&D salaries increased due to staff expansion and the addition of a Vice President of Intellectual Property.
- Financing Activity: The company raised $12.06 million in net proceeds from a public offering of 4.6 million units in February 2007, offsetting operating cash usage.
- Debt Reduction: The $150,000 interest-free loan from the Alberta Heritage Foundation was written down to zero in the deficit due to the adoption of CICA Handbook Section 3855 regarding financial instruments.
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- Positive Interim Results: Announced positive interim results from the Phase Ia/Ib combination trial of REOLYSIN® and radiation. Of 11 patients in the 1a portion, three experienced significant partial responses. Of 6 patients completing the 1b portion, three experienced tumor regression.
- New Trials: Commenced enrollment in a combination trial with docetaxel (Taxotere®) in the U.K. and received approval in October 2007 to begin a unique trial combining REOLYSIN® with cyclophosphamide.
- Intellectual Property: Secured two additional U.S. patents in Q3 2007, bringing the total issued patents to over 150 worldwide.
- Manufacturing: Focused on scaling up production from 20-litre to 40-litre and 100-litre batches.
Financial Guidance
- Cash Usage: Management estimates average monthly cash usage at approximately $1.4 million for 2007.
- Liquidity: With total cash resources of $28.2 million as of September 30, 2007, the company believes its capital is adequate to fund operations well into 2009.
- Future Funding: If additional capital is required, the company intends to seek funding primarily through the issuance of additional equity.
Risks and Contingencies
- Development Stage Risks: No assurance that REOLYSIN® will prove safe and effective in humans or receive regulatory approval.
- Capital Market Volatility: Biotechnology securities are volatile; there is no assurance the company can raise additional funds when needed.
- Manufacturing Dependence: The company currently relies on a single cGMP manufacturer, creating economic dependence risks.
Key Facts for Investor Verification
- Cash Runway: Verify if the $28.2 million cash balance and $1.4 million monthly burn rate are sufficient to reach the next major clinical milestone or funding event without dilution.
- Clinical Trial Enrollment: Confirm the pace of patient enrollment in the seven active trials, particularly the new combination trials with docetaxel and cyclophosphamide.
- Manufacturing Scale-Up: Monitor the success of scaling production to 100-litre batches and the potential engagement of a second cGMP manufacturer to mitigate supply risk.
- Patent Portfolio: Review the scope of the two new U.S. patents issued in Q3 2007 regarding modified herpes simplex viruses and chemotherapy resistance.
- Regulatory Approvals: Track the status of the NCI-sponsored melanoma trial approval expected in late 2007.